The prostate-specific membrane antigen 3 (PSMA3), also known as proteasome 20S subunit alpha 3. is a critical component of the 20S core particle of the proteasome, a multi-subunit complex responsible for ubiquitin-mediated protein degradation in eukaryotic cells. PSMA3 plays a vital role in maintaining cellular homeostasis by regulating the turnover of damaged or misfolded proteins. Antibodies targeting PSMA3 are widely used in research to study proteasome structure, function, and dysregulation in diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. These antibodies enable the detection and quantification of PSMA3 expression via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They also aid in investigating proteasome activity under stress conditions or pharmacological inhibition. PSMA3 antibodies are typically generated using recombinant proteins or synthetic peptides corresponding to conserved regions of the human PSMA3 sequence (UniProt ID: P25788). Validation includes specificity testing in knockout cell lines or tissues to ensure minimal cross-reactivity with other proteasomal subunits. Commercial PSMA3 antibodies are available as monoclonal or polyclonal forms, with clones like 3C2 and EP784Y being commonly cited. Recent studies highlight their utility in exploring proteasome inhibitors' mechanisms and biomarker discovery for diseases linked to impaired protein degradation.